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Background: Recent research has focused on identifying chemical modulators of osteogenesis. We present initial
findings on the osteoinductive properties of prostaglandin Е1 (Vasaprostan), using a rabbit model.
Methods: Data were collected on callus formation in 14 male rabbits. These were divided into two groups (control
and treatment) with 7 animals in each group. In all animals, the right tibia was fractured using a standardized
protocol and stabilized by an intramedullary nail. Treatment group received a 5 μg/kg subcutaneous injection of
PGE1/day during 10 postoperative days. Visual and radiological evaluation of callus formation was prospectively
collected. After 30 days, all animals were killed and the tibia specimens were examined histologically.
Results: In all the treatment group animals, fractures were consolidated radiologically by day 30. No treatment
group animals and two control group animals were excluded form the experiment. In the control group, 4 animals
demonstrated slower callus formation than the main group. Two control group animals were excluded from the
experiment on the 20th day due to wound infection; one developed a nonunion.
The mean coefficient of bone callus thickening in the main group was 2.08 (±0, 16) and 1.77 (±0.05) (p < 0.05) in
the control group. Calculation of mean quantity of neogenic vessels in 10 random visual fields of the bone callus
revealed 78 (±9.82) in the main group and 40 (±4.68) in the control group (p < 0.05).
Conclusions: Our study demonstrates an increased rate and amount of bone callus formation in the group treated
with prostaglandin E1 compared to the control group. Prospective radiological analysis was corroborated by
histologic evaluation.Background
Prostaglandin E1 (PGE1) has general vasodilatory, anti-
thrombotic and endothelium-stabilizing properties. This
is thought to be due to the activation of neutrophil leu-
kocytes and thrombocytes, inhibition of the aggregation
of erythrocytes and an increase of the elastic properties
of erythrocyte cell walls. Furthermore, PGE1 shows fi-
brinolytic activity and was found to increase aerobic tis-
sue respiration. Some literature describes the successful
use of PGE1 in microsurgery for the replantation of ex-
tremities after traumatic amputation [1] and in patients
after transplantation of musculo-cutaneous grafts [2].* Correspondence: andreas.roth@medizin.uni-leipzig.de
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that prostaglandins of the E series had the greatest activ-
ity in bones [3–5]. It was reported in the early 1980s,
that the infusion of PGE1 in human infants with con-
genital cyanotic heart disease led to bone proliferation
on the periosteal surface of long bones after 3–4 weeks
[6–8]. Infants that were given PGE1-infusions to prevent
closure of the ductus arteriosus, developed prominent
periosteal new bone formation. This finding was ob-
served in radiological studies. Subsequently it was noted
that this novel bone became incorporated into the cortex
of the growing appendicular skeleton when PGE1 infu-
sion was stopped [6]. In other early studies of the car-
diovascular effects of prostaglandins, it was observed
that intravenous infusion of PGE1 (25–250 μg/kg/min
for 30 days) led to limb edema and periosteal and endo-
cortical bone proliferation in dogs [9]. In mice, an in-
creased endosteal bone formation has been found ine is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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prostol) [10]. Continuous local infusion of PGE1 (0.5–
2.0 mg/week for 3 weeks) via sublingual cannula onto
the surface of canine mandibles showed a stimulation of
bone proliferation [11]. Both PGE1 and PGE2 locally
injected into the fractured ribs of beagles (0.2 mg twice
a day for 10 days) led to a greater proliferation and a
surface area increase of osteoid on the surface of the
fractured and contralateral non-fractured ribs when
compared to a control group. This finding was more sig-
nificant in the PGE1-group [12, 13]. PGE1 injected dir-
ectly into a tibial cortical defect for the first 10 days led
to a decreased proportion of bone in the callus, but a
greater amount of periosteal new bone formation adja-
cent to the site [14]. From these results, it was con-
cluded that PGE1 promotes differentiation as well as
proliferation of osteoblasts in vivo. Although healing is
not uniformly enhanced, exogenously administered pros-
taglandins have been found to enhance periosteal callus
formation [14].
A comparative dose–response relationship of the effect
of PGE1 on periosteal and intracortical bone in adult
dogs (2–5 years old), infused by an osmotic mini-pump
(0.0 to 16.7 mg PGE1/week) to the lateral mandibular
surface or by controlled-release pellet (0.0 to 16.7 mg
PGE1/week) was determined in a further study [15]. The
proliferation of new bone at sites treated with the pellets
was greatest with the 8.3 mg PGE1/week/three week
treatment. New bone formation was observed, consisting
of woven bone - particularly at sites with high accretion
rates – as well as primary lamellar bone. Increases in the
bone formation rates suggest that PGE1 increased the
recruitment of osteoblasts. Increases in the mineral ap-
positional rate, observed at a higher dose, seem to indi-
cate that PGE1 stimulates bone production at the
cellular level [15].
The synthetic analogue of PGE1 – Alprostadil – is
used medically for obliterating atherosclerosis in vessels
of the lower extremity. Based on the cited data, the au-
thors suggested a possible positive effect of PGE1 in
bone callus formation after fractures. To confirm this
hypothesis, the authors performed a pilot study with an
animal model in order to clarify PGE1’s mechanisms of
action.
To answer the question whether PGE1 influences the
fracture healing it was necessary to determine whether
prostaglandins have an effect on the reparative processes
in the bone tissue of the main group, treated with PGE1.
Methods
The study was approved by a vote of the local ethics com-
mittee of the Pirogov’s Russian National Research Medical
University of Moscow (Protocol№82; 15.12.2008).For our experiment, we selected a model of minimally-
invasive fracture of the tibia diaphysis with subsequent
intramedullary osteosynthesis in rabbits as recommended
by Sachno [16]. We chose this model, because the struc-
ture of a rabbit tibia allows for completely reproducible
fracturing and permits suitable osteosynthesis. In all ani-
mals, the tibia was fractured transversally. Fibular frac-
tures and small tibial bone fragment had no clinical value.
As experimental animals, male rabbits were selected (age
2–3 years, weight 3–5 kg).
The animals were distributed into two groups with 7 ani-
mals in each group. In the control group, the tibia fracture
was stabilized using intramedullary osteosynthesis, and no
further treatment was carried out. In the main group, after
fracturing the tibia and subsequent intramedullary osteo-
synthesis, treatment with PGE1 was performed.
Surgical procedures to create fractures and to stabilize
them were carried out under anesthesia (Rometar
20 mg/ml (2 %), 0.1 mg/kg Zoletil 10 mg/kg subcutane-
ous). Bone diaphysis was exposed through a 1.5 cm skin
incision in the anterior surface of middle third of the
posterior right extremity. Then a 2 mm reamer was used
to create three transversal canals with an angle of 90° to
the bone diaphysis. Next, the bone was manually frac-
tured at this level. For the intramedullary osteosynthesis
two Bogdanov’s nails (ООО “ОСТЕОСИНТЕЗ”, Russia,
Jaroslavskaja Oblast, Gorod Ruibinsk) were used. The
transverse diameter of these Bogdanov’s nails was 1.2 ×
2.4 mm; the length of the nails was determined intraop-
eratively and was 4 – 5 cm. For introduction of the nails
in the intramedullary canal a supplementary 1.5 cm skin
incision was made in projection of the patellar ligament.
Distal to the ligamentous insertion, the intramedullary
canal was opened with an awl. Then the two Bogdanov’s
nails were introduced. The length of the nails was
chosen so that they protruded approximately 1.5 to
2 mm from the bone in order to facilitate subsequent re-
moval. After hemostasis was achieved, the wounds were
closed. Drains and bandages were not used.
The control group of animals received only analgesic
therapy during three postoperative days (Ketoprophenum
3 mg/kg body weight).
In addition to analgesic therapy, the main group of
animals received a 5 μg/kg body weight subcutaneous
injection of PGE1 (Vasaprostan) per day during 10 post-
operative days at the contralateral thigh. The dosage and
duration corresponds to other similar animal experi-
ments [9, 11].
The state of the health of animals was examined dur-
ing the entire postoperative period. Also the status of
the operated limb (visually and manually free motion in
knee and ankle joints, limping or not) and the postoper-
ative wound conditions (visually healing, edema of soft
tissues) were estimated.
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mation, radiologically assessed at defined days, and his-
tologically assessed at day 30.
The radiological examination of operated limbs (ap.
and lateral view) was performed in the supine position
on days 10, 20 and 30 following the operation. On the
X-rays, the size, homogeneity, density, dynamics of bone
callus formation, position of the bone fragments and the
position of intramedullary nails were visually estimated.
On the 30th postoperative day, all animals were killed
in accordance with the humane practice policy of our
institution.
Tibia specimens with their callus were explanted and
released from soft tissues. Intramedullary nails were re-
moved. The bone was used for histological analysis by
cross sections. These were fixed in paraffin and cut
into10 μm layers. Samples were transferred onto micro-
scopic slides and stained using hematoxylin, eosin and
Van-Gieson’s methods. A conventional light microscope
was used to examine the preparations.
To quantify the callus formation in relation to the
bone cortex coefficient between the maximum diameter
of bone with callus and the cortical diameter of native
bone in cross sections of the tibia bone callus was re-
corded. Since the radiological examination could be in-
fluenced by inter- and intra-observer variability, a
further pathomorphological study was performed on the
decalcified slices. Maximum attention was paid to pro-
cesses of neoangiogenesis and chondrocytogenesis. The
quantity of neogenic vessels within the callus of each
slice was counted in 10 random vision fields of light mi-
croscopy with tenfold magnification. Furthermore, theFig. 1 X-ray of the tibia on the 10th day in the main (a) and control (b) gr
bone callusaverage number of vessels was calculated. The average
number of chondrocytes was counted by the same
method, but on 40-fold magnification.
The reliability of the experiment’s results was esti-
mated by the non-parametric Wilkinson’s test for
depended variables and by the Mann–Whitney test for
independent variables. Statistica 7.0 software was used
for performing the tests. The critical value of statistical
error of the first kind was a p-value of 0.05 and less.
Results
State of health
The animals primarily showed signs of slight limping.
Postoperatively, the weight-bearing ability of the extrem-
ity and the range of active motion in nearby joints were
not significantly altered visually and completely restored
after 10–15 days in the main group and after 20–25 days
in the control group.
There were no complications during the postoperative
period in the rabbits of the main group. Two animals of
control group had a severe purulent inflammation of the
soft tissue, so they were excluded from the experiment
on the 20th day.
Radiological examination
On the 10th day, all animals of the main group showed
signs of bone callus formation on x-ray examination
(Fig. 1), whereas the animals in the control group
showed no such signs.
On the 20th day, the same signs of bone callus forma-
tion, which were seen in the main group on day 10, ap-
peared in 4 animals of the control group (Fig. 2). In 3oups. There is more callus formation in group a The arrow point to
Fig. 2 X-ray on the 20th day in the main (a) and control (b) groups. The callus formation in group a had progressed. In group b, 4 animals were
found to have the same callus formation as in group A after 10 days. The arrows point to bone callus
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bone callus formation at this stage. Two of the latter
were excluded from the experiment on 20th day because
of a wound infection.
On the 30th day, in all animals of the main group, the
fractures were radiologically consolidated. In the control
group at this time, 4 animals showed similar callus forma-
tion as the main group on the 20th day (Fig. 3). On the
30th day, one animal in the control group had radiologic-
ally normal bone callus, but morphologically there was a
non-union of fracture. In both groups, during the whole
course, no excessive callus formation was observed.
Histological examination
On the 30th day it was morphometrically established that
the mean coefficient of bone callus thickening in the main
group was 2.08(±0, 16) and in the control group
1.77(±0.05). The difference of 18 %was significant (p <
0.05). The calculation of the mean quantity of neogenic
vessels in 10 random visual fields of the bone callus, re-
vealed 78(±9.82) in the main group and 40(±4.68) in the
control group. This represented an almost twofold in-
crease in the main group (p < 0.05) (Fig. 4).
On the 30th day, the calculation of mean quantity of
chondrocytes revealed 105(±20.03) chondrocytes per 10
fields in the main group and 67(±6.25) in the control
group. This represented almost 150 % in the main group
(p < 0.05) (Fig. 5).
Discussion
The experimental model used in the presented study has
been proven to be suitable to investigate the influence ofPGE1 on fracture healing by its systematic use. The
study has shown that the use of PGE1 in the postopera-
tive period in the main group resulted in a decreased
time to bone consolidation, represented by a faster rate
of bone callus formation. Furthermore, in the control
group, three animals showed no callus formation at day
20. It must, however, be noted that two of these animals
were excluded from the experiment. At day 30 one
animal in the control group still showed no callus for-
mation. In contrast to this, all animals in the main group
showed callus formation during the whole experiment.
These results confirm reports of other authors that
PGE1 has a positive effect on reparative osteogenesis.
Ozturk et al. [17] wrote about the positive effect of
PGE2 in treatment of segmental radial bone defects in
rats. They found a significant healing response in groups
locally treated with PGE2 compared to other animals,
not treated with PGE2 [17]. Li et al. [18] reported that
the EP4 receptor - one of the subtypes of the PGE2
receptor - is a positive regulator in the maintenance of
bone mass and fracture healing [18]. These results
already pointed to an effect of prostaglandins in the con-
text of fracture healing. Hommann et al. [19] used PGE1
systemically in patients after liver transplantation, be-
cause it is known that the majority of liver transplant pa-
tients develop bone mineral density (BMD) loss in the
first 3 to 6 months post transplantation, which leads to
an increased fracture risk. According to the data of the
densitometry at the lumbar spine and the femoral neck,
the authors found a reliable decrease of bone mass loss
in patients who were not given PGE1. Furthermore, in
the PGE1-treated main group, there was a significantly
Fig. 3 X-ray image on the 30-th day in the main (a) and control (b) groups. Fracture is completely consolidated in group a. In group b, the callus
formation is comparable to group a after 20 days. The arrows point to bone callus
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[19]. Shih and Norrdin [12] have observed the positive
effect after oral administration of PGE1 on regional
haversian remodeling in beagles with fractured ribs and
concluded that PGE1 can activate and synchronize re-
modeling cycles among BMUs [20]. All of these works
suggest that PGE1 has an effect on bone formation.
Sherbavskaja (2003) assumed PGE1 as a possible stimu-
lator of bone tissue formation [21]. Similar data were de-
scribed in studies of Riggs and Melton [22] and MarieFig. 4 Neogenic vessels within the fibrous tissue at day 30 in the
main group (HE-staining, 10x magnification). The calculation of
mean quantity of the neogenic vessels in 10 random visual fields of
the bone callus revealed with 78 (±9.82) in the main group a
significant increased number compared to 40 (±4.68) in the
control (p < 0.05)[23], who could show a stimulation of the collagen syn-
thesis and the secretion of insulin-like growth factor 1
(IGF-1) by PGE1. These authors concluded, that PGE1
has anabolic properties on bone tissue and stimulates
bone metabolism.
The histological results of this study confirmed the
radiological findings that there was an increased callus for-
mation following treatment with PGE1. Thus, the mean
coefficient of bone callus thickening was significantly in-
creased in the main group. Furthermore an increased ac-
count of vessels and chondrocytes in the main group
treated with PGE1 as a sign of increased proliferation ofFig. 5 Chondrocytes in the main group at day 30 (HE-staining, 40x
magnification). With 105 (±20.03) chondrocytes per 10 fields in the
main group their number was significantly increased compared to
67 (±6.25) in the control (p < 0.05)
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callus does not necessarily indicate a better fracture heal-
ing, it points to a local effect of PGE1 on the fractured
bone. The work of Shih et al. [12, 13] showed that frac-
tured ribs in the dog under the influence of PGE1 resulted
in an increased formation of osteoid. Here, however, a
local injection was used. PGE2 systemically given to dogs
(6 mg/kg/day orally) during experimental rib fracture
healing, led to a twofold increase in the amount of soft tis-
sue callus at 2 weeks and a comparable increase in the
amount of bony and cartilaginous callus at 6 weeks [24].
Systemic administration of PGE1 to improve fracture
healing, as in the present work, has not been described in
the literature.
Conclusions
The obtained experimental data are convincing and
demonstrate that in a setting of standardized experimen-
tal fracture with intramedullary fixation, the systemic
use of PGE1 in the postoperative period with a dose of
5 μg/kg body weight per day, resulted in a decreased
time period of bone callus formation when compared to
stabilized, but additionally untreated fracture. Nonunion
did not occur. Furthermore, in the main group, the mass
of newly built callus was greater and the quality of the
bone callus can be assumed to be higher, represented by
more vessel and chondrocyte formation. Thus, the
present study updates the data and develops the avail-
able information about the influence of PGE1 on neoan-
giogenesis and stimulation of bone tissue reparation
under systemic application. The animal model used can
be the basis of further investigations. However, the data
of influence in bone tissue reparations after fractures
were received for the first time and must be confirmed
using a larger number of animals and a placebo control
group. For further investigations, a CT analysis and the
histological differentiation and measurement of fibrous
tissue, cartilage and newly formed bone using histomor-
phometric measurements as described from Parfitt et al.
[25] will be necessary. Further biomechanical investiga-
tions are necessary to confirm the estimation that these
fractures heal more rapidly [25]. Regarding the time
period, future studies would have to consider that re-
modelling probably starts after more than 30 days. As
the persistence of chondrocytes was interpreted by other
authors as a sign of delayed bone healing after locally
administered PGE1 into the mandible [26], a longer ob-
serving period should be used in future to show if bone
really develops. In this experiment, some animals failed
in fracture healing due to local infections. Therefore, in
order to guarantee the statistical relevance, future stud-
ies should primarily include more animals in the
investigation.Abbreviations
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